Quotient Bioresearch extends agreement with GE Healthcare to complete transfer into new radiochemistry facility in Cardiff
News Jan 18, 2010
This extension will assure customers of a smooth transition and uninterrupted supply of carbon-14 labelled compounds during the move of Amersham Radiolabelling Services from the existing site to its new state-of-the-art facility in Cardiff this Spring.
At the time of the acquisition in June 2009, Quotient formed its Chemistry & Metabolism business unit and announced a £15 million investment in a new facility in Cardiff. The dedicated facility will be equipped with world-class technology and operate to the highest environmental and safety standards. It will house the largest and most experienced team of radiosynthesis chemists in the world. Now, a timescale for completion and the transfer of production has been confirmed for Spring 2010.
Stephen Lewinton, Managing Director, Quotient Chemistry & Metabolism said: “We are very pleased with the progress of our new building. The extension we have agreed with GE Healthcare allows client work to continue as normal at the existing labs until commissioning of the new facility is completed. This gives us additional capability by allowing transfer of synthesis intermediates with no project delays and provides greater flexibility on completing regulatory processes and validations at the new facility. The bottom line is that we can assure our clients that at no time will all of the labs be closed, and so service can effectively be maintained throughout the transition period.”
Paul Cowan, CEO of Quotient Bioresearch said: “We remain excited by this acquisition and the client feedback we have received since June, and believe it provides a strong cornerstone for our unique ‘synthesis to clinic’ capability. The extension of transitional arrangements with GE Healthcare will remove a great deal of uncertainty concerning our ability to continuously and seamlessly service our client’s needs during this period.”
New Studies Demonstrate Risk Reduction Potential of Heat-Not-Burn Tobacco Products and e-CigarettesNews
Data presented at the Society of Toxicology Annual Meeting (SOT) have demonstrated the potential of two different heat-not-burn tobacco products and e-cigarettes to reduce the risk of smoking-related diseases, in comparison to continued use of conventional cigarettes.READ MORE
Exposure to Low Levels of BPA during Pregnancy Can Lead to Altered Brain DevelopmentNews
New research in mice provides an explanation for how exposure to the widely used chemical bisphenol A (BPA) during pregnancy, even at levels lower than the regulated “safe” human exposure level, can lead to altered brain development and behavior later in life.READ MORE
Moving Toward a Future Free of Drug-Induced Hearing LossNews
A new special publication orchestrated by five of the nation's leading hearing experts compiles the latest research into hearing loss caused by drugs and solvents - how it occurs, how to treat it, and how to prevent it.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018